Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News

An illustration of a brainstorm cloud with the Bioarchitech logo in the centre. Three phrases are connected to the cloud by arrows - oncolytic viruses, protein immunotherapy, and improved outcomes for cancer patients representing Bioarchitech's innovative ideas. Next to each phrase is a lightbulb.

It started with a brainstorm

Companies start in all kinds of different ways, and for Bioarchitech it was brainstorming that generated the idea behind the enterprise. It is now planning a Series A fundraising to bring its lead candidate to the clinic. Bioarchitech is focused on cancer, developing oncolytic viruses encoding protein immunotherapies for the destruction of tumours, ideally with just one or two doses.

Exogene announces strategic collaboration with Immunocore to engineer T-Cell receptors using artificial intelligence

Exogene, a pioneer in the use of generative artificial intelligence (AI) for T-cell receptor (TCR) engineering, has entered into a research collaboration with industry leader Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases.

The Infinitopes team is seen posing with one of their trophies in front of an OBN Awards backdrop.

Infinitopes has a double victory at the 15th Annual OBN Awards 2023

The OBN Awards recognise companies that demonstrate outstanding leadership, innovative practices, and significant contributions towards addressing clinical needs at different stages of development.

Fabiha Ahmed, Apprentice Laboratory Technician at BioEscalator, is pictured in a lab coat while producing ethanol in a lab.

BioEscalator Apprentice Laboratory Technician nominated for Intermediate & Advanced Apprentice Award

Throughout her apprenticeship, Fabiha has shown remarkable determination in learning and mastering the skills required for her role.

A group of individuals standing amidst colourful balloons.

Celebrating 5 years of the Oxford BioEscalator

The BioEscalator recently marked its 5th anniversary with a celebration that showcased the impressive journeys of some of its current and graduated biotech companies.

Hutano Diagnostics acquired by EDX Medical Group

We are delighted that BioEscalator resident start-up Hutano Diagnostics has announced its acquisition by Cambridge, UK-based EDX Medical Group PLC.

Stephanie Lesage, the CEO and Co-founder of Oxford Silk Phage Technologies is pictured holding the BioCap 2023 trophy.

Oxford Silk Phage Technologies wins BioCap 2023 pitch competition

Despite facing tough competition, Oxford Silk Phage Technologies impressed the judges with its presentation, earning the top spot in the competition.

A group of African speakers, two male and two female, standing in front of an audience.

Inspiring stories shared at The Africa Oxford Health Innovation platform programme

The BioEscalator community engaged with the talented cohort of innovators from The Africa Oxford Health Innovation Platform (AfOx-HIP) programme, a collaborative initiative by the University of Oxford fostering innovation and entrepreneurship to address crucial health challenges in Africa.

Dr Khwaja Islam, the Laboratory and Facilities Manager at BioEscalator, dressed in a lab coat and operating a machine.

BioEscalator Laboratory Manager nominated for Apprentice Manager Award

Dr. Khwaja Islam's Apprentice Manager Award nomination shows his commitment to providing excellent apprenticeship training and cultivating a skilled workforce for the future.

A group of people gathered in a park, some sitting on picnic blankets and others standing and chatting. In the background, there are trees and a blue sky.

Building bonds beyond the lab: BioEscalator's Party in the Park 2023

The event provided an excellent opportunity for BioEscalator residents to connect and build relationships with their colleagues and neighbours outside of the workplace. It also offered a much-needed break from the daily work routine.

Audience attending the BioEscalator Pitch Battle 2023, with a speaker presenting at the front and event branding displayed on screens.

BioEscalator Pitch Battle 2023

Pitching a business idea to potential investors is nerve-wracking for any entrepreneur. The pressure to effectively convey a company's vision, potential, and market viability can be overwhelming. However, for the innovative companies associated with the BioEscalator, this task became an opportunity to shine at the fourth annual BioEscalator Pitch Battle.

BioEscalator presented with LEAF Bronze Award at the Vice Chancellor’s Environmental Sustainability Awards 2023

The BioEscalator, alongside resident company Alethiomics, was presented with the award, showing commitment towards sustainable practices.

A photo of the seated audience listening to a presentation at the University of Oxford laboratory services showcase.

Connecting startups to cutting-edge laboratory facilities in Oxford

The BioEscalator and Oxford University Innovation teamed up to hold an event to showcase the state-of-the-art laboratory facilities at the University of Oxford to resident BioEscalator companies and start-ups from the Oxfordshire innovation ecosystem.

Cancer Research Horizons logo

Alethiomics and Infinitopes shortlisted in the New Startup of the Year category for the Cancer Research Horizons Innovation & Entrepreneurship Awards 2022

Alethiomics is uncovering new biology to discover and develop life-changing treatments for patients with blood cancer, and Infinitopes is identifying hidden tumour targets, enabling the creation of high-efficiency vaccines.

Pile of moving boxes

Ochre Bio outgrows the BioEscalator

With Ochre Bio's chemistry laboratory housed at The Oxford Science Park, it was a no-brainer for the company to move over to the park when it outgrew the BioEscalator.

Image of a brain hovering in a person's hands

Mental health in the SME community

Starting up your own business is challenging at the best of times; business plans, funding, licensing and IP are just a few of the hurdles founders face. In addition to the global pandemic and the current financial crisis in the UK, SMEs are under more pressure than ever.

A removal van

The BioEscalator bids farewell to Nucleome Therapeutics

Nucleome Therapeutics has outgrown its space at the BioEscalator and moved to pastures new. The company will continue its growth journey at The Oxford Science Park.

Image of bacteriophage viruses

OSPT selected by INCATEurope as one of the 6 new ventures to receive Stage I support

This new funding will help OSPT refine its regulatory strategy.

The PepGen logo on a map of the USA. A plane is flying from the PepGen logo to where the city of Boston is marked on the map.

PepGen graduates from the BioEscalator

PepGen is the last of the original cohort of companies that moved into the BioEscalator when it first opened. The new PepGen headquarters in Boston, USA, will manage late-stage preclinical testing and clinical and regulatory functions.

The BioEscalator Pitch Battle 2022 audience listening to a pitch.

BioEscalator Pitch Battle 2022

Infinitopes win the battle with an excellent presentation from CEO Jonathan Kwok on how the company is pushing the boundaries of science and medicine to identify hidden tumour targets to create high-efficiency vaccines.